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Eﬁnaconazole  is  a new  triazole  antifungal  for topical  treatment  of onychomycosis.  The  reproduc-
tive  and  developmental  toxicity  of  eﬁnaconazole  was  characterized  in  fertility  and  early  embryonic
development  (rat),  embryo-fetal  development  (rat  and  rabbit),  and  peri/post-natal  development  (rat)
studies  in  accordance  with  current  ICH  guidances.  In the  fertility  study,  maternal  reproductive  toxicity
was  noted  as estrous  cycle  prolongation  (NOAEL  = 5 mg/kg/day)  but  there  were  no  male  reproductive
effects  even  in  the presence  of paternal  toxicity  (NOAEL  = 25 mg/kg/day).  Rat embryo-fetal  and  peri-
natal  pup  lethality  was  the  most  sensitive  (NOAEL  =  5  mg/kg/day)  eﬁnaconazole  developmental  toxicityﬁnaconazole
mbryolethal
riazole
ntifungal
ropylene glycol
YP51
and  was  noted  at  maternally  toxic doses.  Eﬁnaconazole  did  not  affect rabbit  embryo-fetal  development  at
maternally  toxic  doses  (NOAEL  =  10  mg/kg/day).  No malformations  were  induced  by eﬁnaconazole  in rats
or rabbits.  When  compared  with  systemic  exposures  observed  in  onychomycosis  patients,  embryo-fetal
toxicity  in rats  was  noted  at high  (>100-fold)  multiples  of systemic  exposure.
©  2015  The  Authors.  Published  by  Elsevier  Inc.  This  is an  open  access  article  under  the  CC  BY-NC-NDanosterol 14 demethylase
. Introduction
Eﬁnaconazole is a novel triazole marketed in the US, Canada
nd Japan as a topical treatment for onychomycosis, a fungal
nfection of the nails. Like other antifungal triazoles, eﬁnacona-
ole inhibits the fungal cytochrome P450 enzyme lanosterol 14
emethylase (CYP51), thereby disrupting ergosterol synthesis and,
onsequently, membrane integrity and growth in fungi [1]. CYP51
s evolutionarily conserved and, in mammals, mediates conver-
ion of lanosterol to meiosis-activating sterols (MAS); MAS  are
Abbreviations: ICH, international conference on harmonization of technical
equirements for registration of pharmaceuticals for human use; GLP, good labo-
atory practice for nonclinical laboratory studies as established in the United States
ode of Federal Regulations, Title 21, Part 58; GD, gestation day; LD, lactation day;
RHD, maximum recommended human dose; NOAEL, no observed adverse effect
evel; EFT, embryofetal toxicity; LOAEL, lowest observed adverse effect level.
∗ Corresponding author. Tel.: +1 707 796 7225.
E-mail addresses: toxclarity@gmail.com (M.  Glynn), wjo@dowpharmsci.com
W.  Jo), minowa kenji@kaken.co.jp (K. Minowa), sanada hisakazu@kaken.co.jp
H. Sanada), nejishima hiroaki@kaken.co.jp (H. Nejishima),
atsuuchi hiroyuki@kaken.co.jp (H. Matsuuchi), okamura hayao@kaken.co.jp
H. Okamura), rpillai@dowpharmsci.com (R. Pillai), lmutter@dowpharmsci.com
L. Mutter).
1 Present address: ToxClarity, PO Box 6948, Napa, CA 94581, USA.
ttp://dx.doi.org/10.1016/j.reprotox.2014.12.007
890-6238/© 2015 The Authors. Published by Elsevier Inc. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
intermediates in the biosynthesis of cholesterol and may  have a
signaling role in initiating meiosis and oocyte maturation [2,3].
Azoles have higher afﬁnity for fungal CYP51 compared to the mam-
malian enzyme and such selectivity contributes to the safety of this
therapeutic class [4].
Azoles have been reported to produce reproductive and devel-
opmental toxicity in both humans and laboratory animals. The
mechanism is unknown but inhibition of mammalian CYP51 as well
as other CYPs, e.g. CYP17, CYP19 and CYP26, have been postulated
to play a role [5–7]. In rats, ﬂuconazole, voriconazole, and itracona-
zole prolonged gestation and reduced implantation, embryo-fetal
survival, and/or early postnatal survival [8] (2014 package inserts
for Diﬂucan®, Vfend®, Sporanox®). These azoles were teratogenic
producing fetal defects such as cleft palate and hydronephro-
sis/hydroureter. There are case reports in humans of high maternal
exposure to ﬂuconazole during early pregnancy associated with
craniofacial and skeletal abnormalities [8–10].
The present work characterizes the reproductive and develop-
mental toxicity potential of eﬁnaconazole. Studies were conducted
to evaluate the effects of eﬁnaconazole on: (i) fertility and early
embryonic development (rats), from premating to conception
(males) or implantation (females); (ii) embryo-fetal development
(rats and rabbits), from implantation to closure of the hard palate;
and (iii) peri/post-natal development (rats), from implantation
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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iFig. 1. Eﬁnaconazole and H3 metabolite structures.
o weaning and sexual maturity of offspring. Further, the toxi-
okinetics (TK) of eﬁnaconazole and its major human circulating
etabolite, H3, were characterized in plasma (rats and rabbits) and
n milk (rats). The margins of safety based on systemic exposure at
he NOAELs relative to onychomycosis patients are deﬁned.
. Materials and methods
.1. Test chemical
Eﬁnaconazole (Kaken Pharmaceutical Co., Ltd., Shizuoka, Japan),
olecular weight 348.40, is lipophilic with a logP of 3.7. Eﬁnacona-
ole has two  chiral carbons and is the R,R stereoisomer, Fig. 1.
Eﬁnaconazole has two chiral carbons and is the R,R stereoisomer
onﬁguration. H3 is 2-hydroxyl 2-diﬂuorinated phenyl triazole.
.2. Animals, dosing regime and evaluations
Studies were conducted in rats and rabbits per 2005 ICH S5(R2)
Detection of Toxicity to Reproduction for Medicinal Products and
oxicity to Male Fertility) and current GLP guidelines; procedures
ere approved by animal care and use committees, and animal care
as in accordance with the United States Animal Welfare Act regu-
ations (9 CFR, Parts 1, 2, and 3) or “Law Concerning the Protection
nd Control of Animals” (Law No. 105, Japan). All study animals
ere housed in suspended stainless steel wire bottom cages in
limate-controlled rooms. In the perinatal/postnatal study, dams
nd litters were housed in nesting boxes with corn cob nesting
aterial from GD20 – LD20. Studies were conducted in facilities
ompliant with the 1996 NRC Guide for the Care and Use of Labo-
atory Animals.
Doses were selected based on dose range ﬁnding and/or repeat
ose toxicity studies. Eﬁnaconazole was administered as subcuta-
eous (SC) injections once per day at dose volumes of 2 mL/kg in
he rat and 1 mL/kg in the rabbit. Dose solution analysis conﬁrmed
he accuracy of the dose solutions for each study. The SC admin-
stration route achieved a high ratio of systemic exposure to dose
11] and a plasma drug metabolic proﬁle similar to that observed
n humans following topical nail eﬁnaconazole administration [12].
ropylene glycol was used as the vehicle based on drug solubility
nd acceptable tolerability [11]. Topical nail administration is the
linical route in onychomycosis treatment but was  not practical for
onclinical studies.
Toxicity endpoints of viability, clinical observations, body
eights and food consumption were examined in F0 animals and,
n the postnatal development study, F1 pups. Table 1 summarizes
tudy designs and study-speciﬁc evaluations..2.1. Fertility and early embryonic developmental toxicity
ICH 4.1.1)
Male Crj:CD(SPF) rats (approx. 10 weeks old at the start of dos-
ng) were administered eﬁnaconazole or propylene glycol vehiclexicology 52 (2015) 18–25 19
from 28 days prior to mating, through the mating period, until the
day before necropsy (49–53 consecutive days). Females were dosed
from 14 days prior to mating, through the mating period, until ges-
tation day (GD) 7 (23–37 consecutive days). Laparohysterectomies
were performed on GD 14. Dose levels were 0 (vehicle), 1, 5 and
25 mg/kg/day. The high dose was  selected based on results of a
2-week dose range ﬁnder (DRF) study where daily SC eﬁnaconazole
injection of 50 mg/kg/day produced skin thickening and estrous
prolongation (5–7 day cycle) in all rats while 10 mg/kg/day was  bet-
ter tolerated with only 1 of 6 rats with prolonged (6 day) estrous
cycle.
2.2.2. Embryo-fetal developmental toxicity
in rats (ICH 4.1.3)
Crj:CD(SPF) pregnant female rats (approx. 12 weeks old) were
dosed with eﬁnaconazole or vehicle from GD 7 to 17. Dose lev-
els were 0 (vehicle), 2, 10 and 50 mg/kg/day. Laparohysterectomies
were performed and all animals were euthanized on GD 20. Doses
were selected based on a DRF study in pregnant rats. DRF rats were
injected daily with eﬁnaconazole from GD 7 to 17 and the high dose,
50 mg/kg/day, was the maximal tolerated dose based on maternal
and placental toxicity.
2.2.3. Embryo-fetal developmental toxicity in rabbits (ICH 4.1.3)
Pregnant New Zealand White [Hra:(NZW)SPF] female rabbits
(approx. 6 months old) were administered eﬁnaconazole or pro-
pylene glycol vehicle from GD 7 through 20. Dose levels were 0
(vehicle), 1, 5 and 10 mg/kg/day. Animals were evaluated through
GD 29. Laparohysterectomies were performed and all animals were
euthanized on GD 29. Doses were selected based on a DRF  study
in pregnant rabbits in which animals were injected SC daily with
eﬁnaconazole from GD 7 to 20. The DRF high dose, 50 mg/kg/day,
exceeded the maximal tolerated dose and all animals were eutha-
nized on GD 8 due to severe local lesions. The maximal tolerated
DRF dose, 10 mg/kg/day, based on lower body weight gain was
selected as the high dose for the main study. A 3-day pilot study was
conducted in nonpregnant rabbits to determine the tolerability of
lower dose volumes and the lowest volume examined, 1 mL/kg/day,
was selected for the main study.
Blood samples were collected from satellite animals
(3 rabbits/group) prior to dosing and 1, 4, 6, 8 and 24 h after
dose administration on GDs 7 and 20. Plasma was analyzed for
eﬁnaconazole and metabolite H3 concentrations (Section 2.3).
2.2.4. Developmental and perinatal/postnatal reproductive
toxicity (ICH 4.1.2)
Crl:CD(SD) F0 female rats (approx. 10 weeks old) were adminis-
tered eﬁnaconazole or propylene glycol from day 7 of presumed
gestation through day 20 postpartum or day 24 of presumed
gestation (for rats that did not deliver a litter). Dose lev-
els were 0 (vehicle), 1, 5 and 25 mg/kg/day. The high dose
(25 mg/kg/day) was selected based on the maternal toxicity noted
in repeated SC administration of 50 mg/kg/day in pregnant rats
(Section 2.2.2) and severe local toxicity in nonpregnant rats injected
with 40 mg/kg/day (Jo 2014). Fetal death noted at 50 mg/kg/day
in the embryo-fetal developmental toxicity study would preclude
F1 evaluations in the perinatal/postnatal study. Therefore, the high
dose was set below 50 mg/kg and 25 mg/kg was  selected as the high
dose. F1 generation pups were not directly administered eﬁnacona-
zole, but may  have been exposed to eﬁnaconazole or its metabolites
during maternal gestation (in utero exposure) or via maternal milk
during the lactation period.For toxicokinetics evaluation, blood samples were collected
from satellite animals (3 rats/time point/group; 9 animals/group
total) prior to dosing and 0.5, 1, 4, 8, and 24 h after dose admin-
istration on GD 7 and 17 and on lactation day (LD) 20. In addition,
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Table 1
Study design overview.
Study Species (number
animals/group)
Dose levels
(mg/kg/day)
F0 evaluations F1 evaluations
Fertility and early
embryonic
development (ICH
4.1.1)
Rat [Crj:CD(SPF)]
(16 males and 16
females)
0, 1, 5 and 25 Males: Macroscopic pathology
Organ weights (liver, spleen, kidneys,
adrenal glands, prostate, testis,
seminal vesicle, and epididymis)
Histopathology (liver, spleen, skin,
and any tissues with macroscopic
ﬁndings)
Sperm counts, morphology and
motility
Females: Vaginal smears (days until
copulation)
Macroscopic pathology
Number of corpora lutea,
implantations, dead/live embryos,
the indices of insemination,
pre-implantation loss and
post-implantation loss
Histopathology (ovaries, uteri, and
any tissues with macroscopic
ﬁndings)
Not applicable
Embryo-fetal
development (ICH
4.1.3)
Rat [Crj:CD(SPF)]
(20 females)
0, 2, 10 and 50 Macroscopic pathology
Number of corpora lutea,
implantations, dead/live embryos
Indices of implantation and
embryo-fetal mortality
Histopathology of any tissues with
macroscopic ﬁndings
External abnormalities
Fetal weight and sex
Placental weight and diameter
About 50% of fetuses/dam examined
for visceral abnormalities (head,
abdomen, and thoracic organs) and
the remaining fetuses examined for
skeletal abnormalities and
ossiﬁcation progress
Embryo-fetal
development (ICH
4.1.3)a
Rabbit [Hra:(NZW)SPF]
(23 females)
0, 1, 5 and 10 Macroscopic pathology (uteri,
placentae and ovaries)
Placental and gravid uterine weights
Number of fetuses, early and late
resorptions, total implantations and
corpora lutea.
Fetal weight and sex, observation of
all  fetuses for external, visceral and
skeletal malformations and
developmental variations
Peri-/post-natal
development (ICH
4.1.2)a
Rat [Crl:CD(SD)]
(25 females)
0, 1, 5 and 25 Maternal behavior, litter
observations, natural delivery, pup
body weights, viability index (live
pups on LD 4/liveborn pups on LD 1),
lactation index (live pups on LD
21/live pups on LD 4) and dam and
pup necropsy observations
Sexual maturation (vaginal patency
and preputial separation)
Learning and memory (passive
avoidance and M-type watermaze
tests)
Mating performance,
Cesarean-section-enabled counts
and descriptions (implantation sites,
corpora lutea, resorptions, and fetal
survival; placental size, color, and
shape; fetal sex and gross external
observations), testes and
epididymides weights, and necropsy
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aiability, clinical observations, body weights and food consumption examined in F0
a Toxicokinetics were assessed in these studies.
ilk samples were collected from 5 rats/dose group following IV
njection of oxytocin approximately 4 h after dose administration
n LD 14. Plasma and milk were analyzed for eﬁnaconazole and
etabolite H3 concentrations (Section 2.3).
.3. Toxicokinetics
Plasma concentrations of eﬁnaconazole and H3 (Fig. 1) were
etermined in samples collected in the rat peri/postnatal and rabbit
mbryo-fetal development studies using validated (FDA’s Guidance
n Bioanalytical Method Validation, 2001) LC-MS/MS methods. The
ower limit of quantitation for both analytes was 0.10 ng/mL in rats
nd 1.0 ng/mL in rabbits.
Concentrations of eﬁnaconazole and H3 were determined in
at milk using a non-validated, non-GLP LC-MS/MS method with
 lower limit of quantitation of 0.10 ng/mL for both analytes.observations
1 (postnatal development study) animals.
Noncompartmental pharmacokinetic parameters were calcu-
lated using WinNonLin 5.0.1 (Pharsight Corp., Sunnyvale, CA). For
rats, the mean values for the samples at each sampling time were
used for the toxicokinetic analysis.
2.4. Statistical analysis
Data were analyzed for statistically signiﬁcant (p ≤ 0.05) differ-
ences from control values using either parametric or nonparametric
tests based on a statistical decision tree. In rat studies, homogene-
ity of variance was evaluated with Bartlett’s test. Homogeneous
data were analyzed with a post hoc Dunnett’s test if p ≤ 0.05 in a
parametric ANOVA. Nonparametric data (i.e. unequal variance in
Bartlett’s test, p ≤ 0.001) were tested with Kruskal–Wallis ANOVA
followed by Dunnett’s (Seg I and Seg II) or Dunn’s (Seg III) test.
Clinical or other proportion Seg III data were analyzed using the
M. Glynn et al. / Reproductive To
Table  2
Eﬁnaconazole effects on rat estrous cycle length (ICH 4.1.1).
Eﬁnaconazole
(mg/kg/day)
Estrous cycle lengtha Continuous
diestrousa
4 daysb 5 days
0 16/16 (100) 0/16 (0) 0/16 (0)
1  16/16 (100) 0/16 (0) 0/16 (0)
5  15/16 (94) 1/16 (6) 0/16 (0)
25 10/16 (63) 2/16 (13) 4/16 (25)
V
b
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no eﬁnaconazole-related macroscopic ﬁndings were noted for
T
Ea Number animals/total (%).
b Normal estrous cycle length is 4 days.
ariance Test for Homogeneity of the Binomial Distribution. Rab-
it data were processed tested as parametric for selected data
i.e. maternal and fetal body weight, gravid uterine weight and
lacental weight) or nonparametric (all other endpoints). Rabbit
arametric data were tested with ANOVA and Dunnett’s while non-
arametric data were tested with Kruskal–Wallis ANOVA and post
oc Dunn’s.
. Results
.1. Fertility and early embryonic developmental toxicity (ICH
.1.1)
No animals died in any group throughout the experiment, and
o eﬁnaconazole related changes were observed in clinical signs,
ody weight changes and food consumption (data not shown). Local
oxicity, i.e. microscopic subcutaneous irritation and inﬂammation,
as noted in all study groups and thickened skin at the injection
ite was observed at ≥5 mg/kg/day.
In males, absolute and relative spleen weights were
ncreased (25% and 22%, respectively) and slight extramedullary
ematopoiesis was observed at eﬁnaconazole doses of
5 mg/kg/day. Dose-related incidence of microvacuolation of
eripheral hepatocytes in the liver was observed at 5 and
5 mg/kg/day. No other test article effects were noted in study
valuations of males.
In females during the pre-mating phase, the normal 4-day
strous cycle was prolonged by one day in 1/16 (6%) and 2/16 (13%)
nimals in the 5 and 25 mg/kg/day groups, respectively, and 4 high
ose rats had continuous diestrous, Table 2. All estrous cycles recov-
red to normal during the pre-mating period and there was  no
ﬁnaconazole effect on copulation. Three of the 4 animals noted
n constant diestrous during the pre-mating period were success-
ully mated and became pregnant. There were no other test article
ffects on study evaluations of females.
able 3
ﬁnaconazole embryo-fetal toxicity in rats (ICH 4.1.3).
Parameter Eﬁnaconazole (mg/kg/day)
0 (vehicle) 2 
Embryo-fetal deaths (dams with resorptions) 0/19 (0)a 0/20 (0) 
Live  fetusesb 14.47 ± 2.2 (96) 13.7 ± 3.5 
Placental weightb (g) 0.44 ± 0.05 0.46 ± 0.10
Placental diameterb (mm)  13.47 ± 0.68 13.46 ± 1.0
Placental histopathologyc
Decidual cell vacuolar degeneration 0/5 0/5 
Decidua basalis ﬁbrinoid necrosis 0/5 0/5 
Dilation 0/5 0/5 
Fibrinoid deposit 0/5 0/5 
Intervillous hemorrhage 0/5 0/8 
a Number animals/total (%).
b Mean ± SD.
c Examined in the ﬁrst 5 dams/group.
* p ≤ 0.05.xicology 52 (2015) 18–25 21
The paternal and maternal local toxicity NOAELs were
1 mg/kg/kg based on injection site inﬂammation. The fertility
NOAELs were 25 mg/kg/day based on an absence of fertility
effects at the high dose. The NOAEL for estrous prolongation
was 5 mg/kg/day and early embryonic development NOAEL was
25 mg/kg/day based on absence of toxicity ﬁndings at the high dose.
3.2. Embryo-fetal developmental toxicity in rats (ICH 4.1.3)
In dams, local toxicity was observed as injection site
reactions which included thickening of the skin and subcuta-
neous nodules at 10 and 50 mg/kg/day. Eﬁnaconazole depend-
ent systemic effects included reduction in food consumption
(GD15–GD20; 5% decrease; p < 0.05), enlarged spleen, and splenic
extramedullary hematopoiesis and proliferation of megakary-
ocytes at 50 mg/kg/day. No changes in the number of corpora lutea
or implantations were observed.
Signs of eﬁnaconazole embryo-fetal toxicity at the high dose
(50 mg/kg/day) included embryo-fetal deaths, decreased live
fetuses, increased placental weight and, diameter, and microscopic
placental lesions, Table 3.
An increase in the number of unilateral and bilateral rudimen-
tary lumbar ribs was also observed at the high dose (27.2% at
50 mg/kg/day vs. 3.7% at 0 mg/kg/day, p < 0.01) but considered a
skeletal variation and not a fetal malformation [13]. Furthermore,
Marr et al. reported that supernumerary ribs noted prenatally and
on PND 21 were not permanent and disappeared by PND 63 [14].
No eﬁnaconazole-related changes in any other study evaluations
were observed.
The maternal toxicity NOAEL of eﬁnaconazole was 10 mg/kg/day
based on reduced body weight gain and food consumption,
extramedullary hematopoiesis, and local toxicity. The embryo-fetal
toxicity NOAEL was 10 mg/kg/day. The fetal malformation NOAEL
was 50 mg/kg/day based on an absence of malformations at the
high dose.
3.3. Embryo-fetal developmental toxicity in rabbits (ICH 4.1.3)
Three and 2 females in the control and 10 mg/kg/day groups,
respectively, were euthanized after 8–15 days of dosing (between
GD 15 and 22) due to severe lesions at the injection sites. Because
these local effects were observed in control animals, they were
likely due to the irritant properties of propylene glycol. At necropsy,these animals.
Maternal systemic effects included increased incidence of soft
stool and lower (35%) mean body weight gains with a trend
10 50
0/20 (0) 4/20* (20)
(93) 13.7 ± 1.7 (95) 10.7 ± 5.2* (70)
 0.47 ± 0.04 0.80 ± 0.09*
4 13.65 ± 0.78 15.84 ± 0.64*
v. slight-3/5, slight-1/5 slight-4/5
v. slight-1/5 v. slight 1/5, slight-3/5, moderate-1/5
0/5 slight-3/5, moderate-2/5
0/5 v. slight-3/5, slight-2/5
0/5 v. slight-1/5, moderate-1/5
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Table 4
Eﬁnaconazole toxicity in pregnant rabbits (ICH 4.1.3).
Eﬁnaconazole
(mg/kg/day)
Body weight gain (g) Food consumption GD
7–21 (g/animal/day)
GD 7–21 GD 21–29
0 353 ± 174a 11 ± 142 185 ± 41
1  377 ± 132 2 ± 134 181 ± 34
5  316 ± 129 28 ± 148 169 ± 31
10 229 ± 178* 85 ± 110 163 ± 33
f
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Table 6
Eﬁnaconazole effects on lactating rats (ICH 4.1.2).
Eﬁnaconazole
(mg/kg/day)
Body weight gain
GD7–20 (g)
Body weight
LD 1 (g)
Body weight
gain LD 1–4 (g)
0 109 ± 17a 292 ± 19 6 ± 9
1  112 ± 13 290 ± 22 7 ± 9
5  106 ± 11 287 ± 14 8 ± 11
25  109 ± 20 278 ± 17* 16 ± 8**
a Mean ± SD.
*
T
Ea Mean ± SD.
* p ≤ 0.05.
or lower food consumption at 10 mg/kg/day relative to controls,
able 4.
During the post-dosing period between GD 22 and GD 29, body
eight gain became comparable to the control group. No other
ﬁnaconazole-related maternal changes were noted at necropsy,
nd no eﬁnaconazole-related changes in fetal parameters were
bserved.
Exposure (Cmax and AUC) to eﬁnaconazole and H3 increased
ith increasing dose on both GD7 and GD20, Table 5.
The increases in plasma AUC0–24 were approximately linear
rom 1 to 10 mg/kg/day. Eﬁnaconazole exposure increased from
D7 to GD20, indicating drug accumulation with repeated dosing.
xposure to H3 was substantially lower than eﬁnaconazole.
The maternal toxicity NOAEL for eﬁnaconazole was  5 mg/kg/day
GD20 AUC0–24: eﬁnaconazole = 2311 ng h/mL, H3 = 30 ng h/mL)
ased on adverse lower mean body weight gains and decreased
ood consumption at 10 mg/kg/day. The embryo-fetal devel-
pment NOAEL was 10 mg/kg/day (GD20 AUC0–24: eﬁnacona-
ole = 3881 ng h/mL, H3 = 59 ng h/mL) based on the lack of effects on
mbryo-fetal development at the highest dosage level evaluated.
.4. Developmental and perinatal/postnatal reproductive toxicity
ICH 4.1.2)
No test article related deaths and no dose-dependent increases
n adverse clinical ﬁndings were observed in the F0 generation
uring the gestation period. At necropsy, adhesions of abdominal
rgans or tissues occurred in all dosage groups (in ≥12% of ani-
als per dose group), with slightly greater incidence at 5 (20% of
nimals) and 25 (24% of animals) mg/kg/day. These ﬁndings were
onsistent with other repeat-dose SC rat toxicity studies with this
est article and vehicle [11]. These adhesions were likely related
o the spread of inﬂammation related to SC administration of the
ropylene glycol vehicle and exacerbated with apparent dose-
ependence by eﬁnaconazole.
Eﬁnaconazole did not affect body weight and body weight gain
uring the gestation period. However, LD 1 body weight was signif-
cantly reduced (6.6%, p ≤ 0.05) in the 25 mg/kg/day dosage group,
able 6.
This weight loss was not correlated with litter size. Mater-
al body weight gain during LDs 1 through 4 was signiﬁcantly
able 5
ﬁnaconazole and H3 plasma exposure in pregnant rabbits (ICH 4.1.3).
Dose (mg/kg/day) Day of dosing Eﬁnaconazole 
Cmax (ng/mL) 
1 GD 7 18.6 ± 5.4a
GD20 51 ± 4.0 
5 GD 7 164 ± 106 
GD20 284 ± 109 
10 GD  7 193 ± 80 
GD20 334 ± 89 
a Mean ± SD.p ≤ 0.05.
** p ≤ 0.01.
increased (46%, p ≤ 0.01) at 25 mg/kg/day; this weight gain was
not correlated with the number of pups found dead on lactation
day 1, suggesting the difference from control was not related to
lower nutritional demand. Body weight gains were then generally
comparable among the four groups for the remainder of the lacta-
tion period. No test-article related changes in absolute and relative
feed consumption were observed during either the gestation or
lactation periods.
Eﬁnaconazole increased perinatal pup mortality at
25 mg/kg/day, Table 7.
Mean liveborn litter size was slightly reduced (1.6%) while the
numbers of pups found dead on LD 1 and on LDs 2 through 4 were
signiﬁcantly increased and viability index decreased (10%).
No test article-related deaths, clinical ﬁndings, and necropsy
ﬁndings were observed in the F1 generation after weaning. No test-
article related changes were observed during the post-weaning,
pre-cohabitation and/or gestation periods.
In F1 pups, there were no effects on neurological development
as evaluated in passive avoidance and water maze tests. There were
no effects on sexual maturation in F1 pups. The average day that
preputial separation for male rats occurred earlier at 25 mg/kg/day,
44.2 ± 2.2, relative to vehicle controls, 46.2 ± 2.9, but was within the
observed historical ranges at the Testing Facility and not considered
toxicologically important.
No test article-related effects on reproductive development
were observed in the F1 generation. There were no test article-
related fetal gross external alterations.
Maternal systemic exposure (Cmax and AUC0–24) to eﬁnacona-
zole and H3 increased with increasing dose on GD7, GD17 and
LD 20, Table 8. Cmax and AUC increased from GD 7 to GD 17 but
generally decreased from GD17 to LD 20.
Eﬁnaconazole and H3 were detected in milk collected 4 h after
dosing on LD 14 Table 9.
In rats dosed at 1, 5 and 25 mg/kg, milk concentrations for
eﬁnaconazole increased in a less than dose proportional relation-
ship while H3 metabolite levels were roughly dose proportional.
In contrast to plasma, the concentrations of eﬁnaconazole were
substantially higher than H3 in milk, which may  be explained
by the higher lipophilicity of eﬁnaconazole compared to H3.
Excretion of eﬁnaconazole and H3 into milk correlated with
H3
AUC0–24 (ng h/mL) Cmax (ng/mL) AUC0–24 (ng h/mL)
181 ± 38 0 0
384 ± 63 0 0
1242 ± 346 2.3 ± 1.1 20.5 ± 11.9
2311 ± 461 3.3 ± 0.6 37.6 ± 15.6
2355 ± 521 3.1 ± 0.8 48.2 ± 22.8
3881 ± 804 4.0 ± 0.6 59.4 ± 14.5
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Table  7
Eﬁnaconazole effects on rat peri and postnatal survival (ICH 4.1.2).
Eﬁnaconazole (mg/kg/day) Liveborn pups Litter sizeb Perinatal pup mortalitya Viability indexc Lactation indexd
LD 1 LD 2–4
0 317 13.8 ± 2.4 0/317 (0) 6/317 (1.9) 311/317 (98.1%) 305/311 (98.1)
1  332 13.3 ± 1.4 1/332 (0.3) 5/331 (1.5) 326/332 (98.2%) 323/326 (99.1)
5  311 13.5 ± 1.9 5/311 (1.6) 3/306 (1.0) 303/311 (97.4%) 285/303** (94.0)
25  266 11.6 ± 3.3 13/266 (4.9)** 20/253 (7.9)** 233/266 (87.6%)** 232/233 (99.6)
a Number dead/total number pups in dose group (%).
b Mean ± SD (%).
c Number of live pups on LD4/number of liveborn pups on LD1.
d Number of live pups on LD21/number of live pups on LD4.
** p ≤ 0.01.
Table 8
Toxicokinetics of eﬁnaconazole and H3 in plasma of pregnant and lactating rats (ICH 4.1.2).
Eﬁnaconazole (mg/kg/day) Day of dosing Eﬁnaconazole H3
Cmax (ng/mL) AUC0–24 (ng h/mL) Cmax (ng/mL) AUC0–24 (ng h/mL)
1 GD 7 7.11 54.9 15.1 219
GD17 14.5 120 17.8 290
LD20 9.15 85.8 19.1 241
5 GD  7 38.1 364 56.7 913
GD17 46.4 552 113 1602
LD20 29.1 422 84.5 1131
25 GD  7 57.7 1033 145 2567
GD17 189 
LD20 128 
Table 9
Concentrations of eﬁnaconazole and H3 in milk of lactating rats (Seg III).
Eﬁnaconazole
(mg/kg/day)
Concentration on lactation day
14, 4 h post-dosing (ng/mL)a
Eﬁnaconazole H3
1 54.1 ± 24.9 11.0 ± 3.0
5  1536 ± 1232 52.4 ± 20.8
d
d
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r
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b
m
CYP26 has not been studied. Eﬁnaconazole does inhibit some drug25  2157 ± 662 256 ± 59
a Mean ± SD.
ecreases in the plasma exposures (AUC) between GD 17, when
ams are not producing milk, and LD 20.
The maternal toxicity NOAEL for eﬁnaconazole is 5 mg/kg/day
LD20 AUC0–24: eﬁnaconazole = 422 ng h/mL, H3 = 1131 ng h/mL)
ased on injection site reactions and LD 1 body weight loss. The
eproductive toxicity NOAEL in the dams is 25 mg/kg/day based
n the lack of effects at the high dose. The NOAEL for viability in
he offspring is 5 mg/kg/day based on increased perinatal pup mor-
ality, reduced liveborn litter size, and increased pup mortality on
actation days 1 through 4 observed at 25 mg/kg/day.
. Safety assessment
Topical eﬁnaconazole 10% solution has demonstrated safety and
fﬁcacy in the treatment of onychomycosis [15–17]. In onychomy-
osis patients, the highest individual AUC0–24 h at the maximum
ecommended human dose (MRHD) was 25.3 ng h/mL for eﬁna-
onazole and 141.5 ng h/mL for metabolite H3 [12]. Safety factors
ased on comparison of animal NOAEL eﬁnaconazole AUC expo-
ures to human AUC were calculated for developmental and
eproductive toxicity, Table 10.
TK exposure was not measured in the rat fertility and embryo-
etal developmental toxicity studies so exposure was  estimated
ased on 2821 ng h/mL female day 90 AUC at 10 mg/kg/day deter-
ined in a 6-month SC repeat dose rat toxicity study [11].3363 373 8186
2253 276 5810
5. Discussion
Eﬁnaconazole treatment during gestation produced develop-
mental toxicity in rats but not rabbits; F1 survival and placental
effects were the most sensitive endpoints. Effects on F1 survival
were consistent in both the embryo-fetal developmental study
and the perinatal/postnatal study. Embryo-fetal and early postna-
tal mortality manifested as decreased liveborn litter size and/or
increased neonatal death, while placental effects presented as
increased weight and diameter, vacuolar degeneration and ﬁbri-
noid necrosis. These rat developmental toxicities are common to
both drug and pesticide azole products [5] (Vfend). The perinatal
and postnatal study results agree with results from the rat develop-
mental study and there were no eﬁnaconazole effects on F1 sexual
maturation, reproductive function or neurological development.
Although many antifungal azoles are teratogenic, eﬁnacona-
zole did not induce malformations in rats and rabbits. Teratogenic
azole antifungals include ketoconazole, itraconazole, ﬂuconazole
and voriconazole (2013 package insert for Extina®; Sporanox, Diﬂu-
can, Vfend). The differences in teratogenicity ﬁndings between
eﬁnaconazole and teratogenic azoles may  be due to systemic expo-
sure and/or intrinsic activity at the azole teratogenicity target(s).
Exposure data at teratogenic doses for most azole drugs is not
available but a comparison of voriconazole teratogenic exposure
to eﬁnaconazole can be made. Voriconazole rat teratogenic effects
occurred at exposures more than 10-fold above the eﬁnaconazole
high dose exposure (Vfend). Intrinsic teratogenic activity of eﬁna-
conazole is difﬁcult to determine as the azole teratogenic target is
not known although there are several proposed targets, including
CYPs (e.g. CYP51, CYP19 and CYP26) and Hox gene expression.
Antifungal azoles are known to inhibit mammalian cytochrome
P450 enzymes (CYP) in addition to the fungal target enzyme
[5]. Eﬁnaconazole inhibition of mammalian CYP51, CYP19 andmetabolizing CYP enzymes, CYP2C9 and CYP3A4, in vitro at sub-
micromolar concentrations (Jublia 2013 FDA  Summary Basis of
Approval). Several antifungal azoles have been reported to inhibit
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Fig. 2. Species differences in plasma parent drug and metabolite exposure.
Table 10
Eﬁnaconazole developmental and reproductive safety.
Study Endpoint(s) Eﬁnaconazole (mg/kg/day) AUC (ng h/mL) AUC ratio animal/MRHDb
Fertility and early embryonic
developmental toxicity
Fertility NOAEL 25 7052a 279
Prolonged estrous NOAEL 5 1411a 56
Rat  developmental toxicity EFT LOAEL and malformation NOAEL 50 14105a 559
EFT  NOAEL 10 2821a 112
Rabbit developmental toxicity EFT and malformation NOAEL 10 3881 154
Developmental and
perinatal/postnatal toxicity
EFT LOAEL and postnatal NOAEL 25 2253 89
EFT  NOAEL 5 422 17
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ta Estimate based on female day 10 mg/kg/day 90 AUC in 6-month subcutaneous 
b Highest individual AUC at the maximum recommended human dose.
YP19 (aromatase), a key enzyme in the biosynthesis of estro-
en [6], at sub-micromolar (e.g. bifonazole IC50 = 0.02 M) to high
icromolar (e.g. ﬂuconazole IC15 = 140 M)  concentrations [18].
nhibition of CYP19 results in lower estrogen levels, and estrogen
ecreases were noted in epoxiconazole, ketoconazole, ﬂuconazole,
nd voriconazole rat developmental toxicity studies [19] (Diﬂucan;
fend). Lower estrogen during rat gestation is associated with a
ariety of effects including increased placental weights and prolon-
ation of parturition (Diﬂucan). Estrogen levels were not measured
n the eﬁnaconazole studies, but the ﬁnding of increased placen-
al weights in rats is consistent with lower estrogen due to CYP19
nhibition.
Teratogenicity has been associated with ablation or reduction of
YP51 activity; CYP51 knock-out mice develop skeletal and cardiac
alformations, consistent with ﬂuconazole-induced teratogenic-
ty, although potency for CYP51 inhibition and teratogenicity do
ot correlate [7–10,20].
CYP26 inhibition is also a proposed azole teratogenic target [5].
YP26 catabolizes retinoic acid, a well-established teratogen. In
nimals, azole antifungals produce a spectrum of malformations
imilar to patterns of retinoic acid teratogenicity (i.e. craniofacial
nd axial defects), and in vitro, azoles modulate gene expression in
mbryos similar to retinoic acid [21]. Retinoic acid is important to
xial speciﬁcation during normal embryonic development via Hox
enes expression and alterations of embryonic retinoic acid levels
eads to dysmorphogenesis [22]. Eﬁnaconazole was not teratogenic
nd has not been tested for inhibition of mammalian CYP51 or
YP26 or effects on gene expression.
Eﬁnaconazole was embryotoxic in rats but not rabbits; eﬁna-
onazole exposures were roughly equivalent between the rat and
abbit while metabolite H3 exposures in the rat were 100-fold
igher than in the rabbit, Fig. 2.
These data may  suggest a role for H3 in embryo-fetal mor-
ality but H3 embryotoxicity has not been investigated. Another dose rat toxicity study.
explanation is that other azoles (e.g. ketoconazole, itraconazole
and ﬂuconazole) are teratogenic in rats but not rabbits [23]; thus,
species differences in eﬁnaconazole toxicity may  be due to species
sensitivities and not to the H3 metabolite.
No effects of eﬁnaconazole on rat fertility or early embryonic
development were observed at the high dose (25 mg/kg/day) or,
based on estimated AUC, 279 times the maximum human exposure
in onychomycosis therapy. The lack of eﬁnaconazole effects on rat
fertility is consistent which other pharmaceutical azoles (itracona-
zole, voriconazole and ﬂuconazole) and differs from ketoconazole
impairment of rat fertility. The estrous prolongation NOAEL was
5 mg/kg/day, 56-fold higher than the MRHD AUC. No fetal malfor-
mations were found at the rat developmental toxicity high dose,
50 mg/kg/day (559-fold MRHD). Embryo-fetal toxicity was noted
at the high dose with a 10 mg/kg/day NOAEL or 112-fold MRHD.
The rabbit developmental toxicity NOAEL establishes a 154-fold
exposure multiple for eﬁnaconazole. The dose levels in the perina-
tal and postnatal rat developmental study were slightly different
compared to the developmental toxicity study and are probably
the reason for differences in NOAELs. The perinatal NOAEL estab-
lishes a 17-fold exposure multiple for eﬁnaconazole compared to
human exposure at the MRHD. These exposure multiples support
the safety of topical eﬁnaconazole treatment of onychomycosis.
6. Conclusions
Eﬁnaconazole reproductive and developmental toxicity
included F1 mortality, placental effects and estrous cycle pro-
longation. These toxicities are consistent with marketed azole
antifungal drugs. Unlike many marketed azole antifungals eﬁ-
naconazole was not teratogenic. Eﬁnaconazole did not affect
embryo-fetal development in rabbits even in the presence of
maternal toxicity.
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When compared with maximal systemic exposures observed in
nychomycosis patients treated with topical nail administration of
ﬁnaconazole 10% solution, developmental and reproductive tox-
city in rats was noted only at high (>100-fold) multiples of human
ystemic exposure.
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